Shavit Capital Fund News
2 articles
growth-positive
Shavit Capital raises $100m for fifth fund
Shavit Capital, founded and managed by Gary Leibler, has completed a $100 million funding round for its fifth fund. The firm specializes in pre-IPO investments in life-sciences companies, with a focus on the technology sector. Shavit Capital plans to expand its activities to include companies nearing flotation in other markets. It works closely with leading international investment banks and leads investment rounds ranging from $20 million to $60 million. The firms portfolio includes companies like Foamix Pharmaceuticals, Kamada, and PolyPid. Shavit Capitals recent notable funding round was a $40 million round for Gamida Cell, which completed an IPO on Nasdaq and raised $50 million. The firms partners include Leon Recanati, Jonathan Leibler, Gabriel Menaged, and Erez Yuval.
InvestmentExpand
growth-positive
Shavit Capital raises $75m Israel start-up fund
Shavit Capital Fund, headed by managing director Gary Leibler, has raised $75 million from investors mainly from the US. The fund will invest at least 50% of its money in biomed. The previous funds managed by Shavit Capital invested in companies such as ReWalk Robotics, Foamix Pharmaceuticals, SuperDerivatives, Kamada Ltd., and Brainsway Ltd. The new fund is expected to operate according to a unique model of a minority investment without any demand for a place on the board of directors. Shavit Capitals success depends on a continued active window for offerings.
Investment
